zanubrutinib 160 mg BID orally
KY-2023-044-02
Unknown small_molecule active
Quick answer
zanubrutinib 160 mg BID orally for Primary Central Nervous System Lymphoma is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Primary Central Nervous System Lymphoma
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active